Clinical Trials Browser

Phase 1/2 × INDUSTRY × oregovomab × Clear all

NCT04938583 2026-04-06

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Phase 1/2 Active not recruiting

Ovarian Neoplasms

NCT00034138 2007-12-18

A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma

Phase 1/2 Terminated

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms